Venetoclax directly binds and inhibits BCL-2 as a BH3 mimetic, displacing pro-apoptotic BH3-only proteins to activate BAX/BAK, trigger mitochondrial outer membrane permeabilization, cytochrome c release, and caspase-mediated intrinsic apoptosis in BCL-2–dependent cells.